SGLT2-independent effects of canagliflozin on NHE3 and mitochondrial complex I activity inhibit proximal tubule fluid transport and albumin uptake
Am J Physiol Renal Physiol. 2024 Apr 25. doi: 10.1152/ajprenal.00005.2024. Online ahead of print.ABSTRACTBeyond glycemic control, SGLT2 inhibitors (SGLT2i) have protective effects on cardiorenal function. Renoprotection has been suggested to involve inhibition of NHE3 leading to reduced ATP-dependent tubular workload and mitochondrial oxygen consumption. NHE3 activity is also important for regulation of endosomal pH, but the effects of SGLT2i on endocytosis are unknown. We used a highly differentiated cell culture model of proximal tubule (PT) cells to determine the direct effects of SGLT2i on Na+-dependent fluid transport...
Source: Am J Physiol Renal P... - April 25, 2024 Category: Urology & Nephrology Authors: Wafaa N Albalawy Elynna B Youm Katherine E Shipman Keelan J Trull Catherine J Baty Kimberly R Long Youssef Rbaibi Xue-Ping Wang Olayemi G Fagunloye Katharine A White Michael J Jurczak Ossama B Kashlan Ora A Weisz Source Type: research
SGLT2-independent effects of canagliflozin on NHE3 and mitochondrial complex I activity inhibit proximal tubule fluid transport and albumin uptake
Am J Physiol Renal Physiol. 2024 Apr 25. doi: 10.1152/ajprenal.00005.2024. Online ahead of print.ABSTRACTBeyond glycemic control, SGLT2 inhibitors (SGLT2i) have protective effects on cardiorenal function. Renoprotection has been suggested to involve inhibition of NHE3 leading to reduced ATP-dependent tubular workload and mitochondrial oxygen consumption. NHE3 activity is also important for regulation of endosomal pH, but the effects of SGLT2i on endocytosis are unknown. We used a highly differentiated cell culture model of proximal tubule (PT) cells to determine the direct effects of SGLT2i on Na+-dependent fluid transport...
Source: American Journal of Physiology. Renal Physiology - April 25, 2024 Category: Physiology Authors: Wafaa N Albalawy Elynna B Youm Katherine E Shipman Keelan J Trull Catherine J Baty Kimberly R Long Youssef Rbaibi Xue-Ping Wang Olayemi G Fagunloye Katharine A White Michael J Jurczak Ossama B Kashlan Ora A Weisz Source Type: research
Effects of sodium-glucose cotransporter 2 inhibitors on bone metabolism in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
Sodium glucose cotransporter 2 (SGLT2) inhibitors are widely used in type 2 diabetes mellitus (T2DM) therapy. The impact of SGLT2 inhibitors on bone metabolism has been widely taken into consideration. But the... (Source: BMC Endocrine Disorders)
Source: BMC Endocrine Disorders - April 24, 2024 Category: Endocrinology Authors: Jing Wang, Xin Li, Yang Li and Chen Lei Tags: Research Source Type: research
Sodium-Glucose Co-transporter 2 Inhibitors and Mycotic Genital or Urinary Tract Infections in Heart Failure
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have proven benefits on clinical outcomes in patients with heart failure (HF).1-6 However, this class of medications increases the risk of mycotic genital infections (MGIs) and urinary tract infections (UTIs), particularly within the first 3-6 months after their initiation.7,8,9 In the EMPEROR-Preserved and EMPEROR-Reduced trials, MGIs and UTIs were among the 3 most common adverse events in the empagliflozin group,1,2 highlighting the clinical relevance of these infections. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - April 24, 2024 Category: Cardiology Authors: Angela Duvalyan, Ricardo M. La Hoz, Darren K McGuire, Mark H. Drazner Tags: Review Article Source Type: research
Investigating the impact of empagliflozin on the retina of diabetic mice
CONCLUSION: EMPA mitigates inflammation and preserves BRB structure and function, suggesting that it may prevent DR or serve as an effective early treatment for DR.PMID:38653578 | DOI:10.1177/11206721241247585 (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - April 23, 2024 Category: Opthalmology Authors: Juan Chen Shenghui Zhang Yao You Siqi Hu Jiake Tang Chen Chen Wen Wen Ting Tang Qingwen Yu Xuhan Tong Chunyi Wang Wenbin Zhao Xinyan Fu Xingwei Zhang Mingwei Wang Wenyan Gong Source Type: research
Investigating the impact of empagliflozin on the retina of diabetic mice
CONCLUSION: EMPA mitigates inflammation and preserves BRB structure and function, suggesting that it may prevent DR or serve as an effective early treatment for DR.PMID:38653578 | DOI:10.1177/11206721241247585 (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - April 23, 2024 Category: Opthalmology Authors: Juan Chen Shenghui Zhang Yao You Siqi Hu Jiake Tang Chen Chen Wen Wen Ting Tang Qingwen Yu Xuhan Tong Chunyi Wang Wenbin Zhao Xinyan Fu Xingwei Zhang Mingwei Wang Wenyan Gong Source Type: research
The effects of SGLT2 inhibitors on right ventricle functions in heart failure patients: Update meta-analysis of the current literature
Kardiol Pol. 2024 Apr 19. doi: 10.33963/v.phj.100199. Online ahead of print.NO ABSTRACTPMID:38638090 | DOI:10.33963/v.phj.100199 (Source: Polish Heart Journal)
Source: Polish Heart Journal - April 19, 2024 Category: Cardiology Authors: Tufan Cinar Faysal Saylik Vedat Cicek Levent Pay Aleksan Khachatryan Joel Alejandro Almina Erdem Mert Ilker Hayiroglu Source Type: research
The effects of SGLT2 inhibitors on right ventricle functions in heart failure patients: Update meta-analysis of the current literature
Kardiol Pol. 2024 Apr 19. doi: 10.33963/v.phj.100199. Online ahead of print.NO ABSTRACTPMID:38638090 | DOI:10.33963/v.phj.100199 (Source: Kardiologia Polska)
Source: Kardiologia Polska - April 19, 2024 Category: Cardiology Authors: Tufan Cinar Faysal Saylik Vedat Cicek Levent Pay Aleksan Khachatryan Joel Alejandro Almina Erdem Mert Ilker Hayiroglu Source Type: research
Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians
CONCLUSION: In adults with T2DM, SGLT2 inhibitors and GLP1 agonists (but not DPP4 inhibitors, insulin, or tirzepatide) reduce all-cause mortality and MACE compared with usual care. SGLT2 inhibitors reduce CKD progression and heart failure hospitalization and GLP1 agonists reduce stroke compared with usual care. Serious adverse events and severe hypoglycemia are less frequent with SGLT2 inhibitors and GLP1 agonists than with insulin or SU.PRIMARY FUNDING SOURCE: American College of Physicians. (PROSPERO: CRD42022322129).PMID:38639549 | DOI:10.7326/M23-1490 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - April 19, 2024 Category: Internal Medicine Authors: Tyler Drake Adrienne Landsteiner Lisa Langsetmo Roderick MacDonald Maylen Anthony Caleb Kalinowski Kristen Ullman Charles J Billington Anjum Kaka Shahnaz Sultan Timothy J Wilt Source Type: research
Emerging therapies: Potential roles of SGLT2 inhibitors in the management of pulmonary hypertension
Respir Med. 2024 Apr 15:107631. doi: 10.1016/j.rmed.2024.107631. Online ahead of print.ABSTRACTPulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple clinical conditions and may be associated with a variety of cardiovascular and respiratory diseases. Pulmonary hypertension due to left heart disease (PH-LHD) currently lacks targeted therapies, while Pulmonary arterial hypertension (PAH), despite approved treatments, carries considerable residual risk. Metabolic dysfunction has been linked to the pathogenesis and prognosis of PH through various studies, with emerging metabolic agents offering ...
Source: Respiratory Care - April 17, 2024 Category: Respiratory Medicine Authors: Taimin Luo Hui Wu Wanlong Zhu Liaoyun Zhang Yilan Huang Xuping Yang Source Type: research
Emerging therapies: Potential roles of SGLT2 inhibitors in the management of pulmonary hypertension
Respir Med. 2024 Apr 15:107631. doi: 10.1016/j.rmed.2024.107631. Online ahead of print.ABSTRACTPulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple clinical conditions and may be associated with a variety of cardiovascular and respiratory diseases. Pulmonary hypertension due to left heart disease (PH-LHD) currently lacks targeted therapies, while Pulmonary arterial hypertension (PAH), despite approved treatments, carries considerable residual risk. Metabolic dysfunction has been linked to the pathogenesis and prognosis of PH through various studies, with emerging metabolic agents offering ...
Source: Respiratory Care - April 17, 2024 Category: Respiratory Medicine Authors: Taimin Luo Hui Wu Wanlong Zhu Liaoyun Zhang Yilan Huang Xuping Yang Source Type: research
Effects of SGLT2 inhibitors on cause-specific cardiovascular death in patients with chronic kidney disease: a meta-analysis of CKD progression trials
Clin J Am Soc Nephrol. 2024 Apr 16. doi: 10.2215/CJN.0000000000000470. Online ahead of print.NO ABSTRACTPMID:38622766 | DOI:10.2215/CJN.0000000000000470 (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - April 16, 2024 Category: Urology & Nephrology Authors: Robert A Fletcher William G Herrington Rajiv Agarwal Kaitlin J Mayne Clare Arnott Meg J Jardine Kenneth W Mahaffey Vlado Perkovic Natalie Staplin David C Wheeler Glenn M Chertow Hiddo J L Heerspink Brendon L Neuen Source Type: research
Effects of SGLT2 inhibitors on cause-specific cardiovascular death in patients with chronic kidney disease: a meta-analysis of CKD progression trials
Clin J Am Soc Nephrol. 2024 Apr 16. doi: 10.2215/CJN.0000000000000470. Online ahead of print.NO ABSTRACTPMID:38622766 | DOI:10.2215/CJN.0000000000000470 (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - April 16, 2024 Category: Urology & Nephrology Authors: Robert A Fletcher William G Herrington Rajiv Agarwal Kaitlin J Mayne Clare Arnott Meg J Jardine Kenneth W Mahaffey Vlado Perkovic Natalie Staplin David C Wheeler Glenn M Chertow Hiddo J L Heerspink Brendon L Neuen Source Type: research
Emerging therapies: Potential roles of SGLT2 inhibitors in the management of pulmonary hypertension
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple clinical conditions and may be associated with a variety of cardiovascular and respiratory diseases. Pulmonary hypertension due to left heart disease (PH-LHD) currently lacks targeted therapies, while Pulmonary arterial hypertension (PAH), despite approved treatments, carries considerable residual risk. Metabolic dysfunction has been linked to the pathogenesis and prognosis of PH through various studies, with emerging metabolic agents offering a potential avenue for improving patient outcomes. (Source: Respiratory Medicine)
Source: Respiratory Medicine - April 14, 2024 Category: Respiratory Medicine Authors: Taimin Luo, Hui Wu, Wanlong Zhu, Liaoyun Zhang, Yilan Huang, Xuping Yang Source Type: research
SGLT2 inhibitor monotherapy alleviates hyperglycemia in heredity severe insulin resistance syndrome
Chin Med J (Engl). 2024 Apr 10. doi: 10.1097/CM9.0000000000003108. Online ahead of print.NO ABSTRACTPMID:38602155 | DOI:10.1097/CM9.0000000000003108 (Source: Chinese Medical Journal)
Source: Chinese Medical Journal - April 11, 2024 Category: General Medicine Authors: Huixuan Wu Junaid Iqbal Long Li Hongli Jiang Chen Chao Meibiao Zhang Ou Li Houde Zhou Source Type: research
